<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117608</url>
  </required_header>
  <id_info>
    <org_study_id>LIPOJOINT</org_study_id>
    <nct_id>NCT03117608</nct_id>
  </id_info>
  <brief_title>A Single Intra-articular Injection of aMAT vs PRP in Patients With OA of the Knee</brief_title>
  <acronym>LIPOJOINT</acronym>
  <official_title>A SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY OF A SINGLE, INTRA-ARTICULAR INJECTION OF AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT) VERSUS (VS) PRP IN PATIENTS WITH OSTEOARTHRITIS (OA) OF THE KNEE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lipogems International spa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lipogems International spa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study proposes to compare performances and safety of intra-articular injections of aMAT
      with those of a control group (PRP injections) for the treatment of symptomatic OA of the
      knee. The end-points will be determined evaluating the performances of the treatment group in
      terms of improvement of the symptomatology, functional recovery and radiological appearance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial is a prospective, randomized, controlled, two-arm, single-blind study,
      involving 118 patients affected by symptomatic OA of the knee joint. Eligible subjects will
      be randomly allocated to one of the two treatment groups, with a 1:1 randomization ratio.
      Respectively, 59 patients treated with a single intra-articular injection of aMAT, and 59
      patients treated with a single intra-articular injection of PRP.

      The patients enrolled in the study will be treated according to the study protocol and
      followed after treatment with periodic visits and diagnostic imaging examinations, as
      Magnetic Resonance Imaging at twelve and twenty-four months follow-up and X-Ray, at three,
      six, twelve, and twenty-four months of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">February 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 24, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Time Frame: 24 months evaluation</time_frame>
    <description>Safety of the procedure, documenting characteristics and incidence of adverse events.(AE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical improvement documented with IKDC(International Knee Documentation Committee) score and KOOS (Knee Injury and Osteoarthritis Outcome Score)</measure>
    <time_frame>Time Frame: 6 months evaluation</time_frame>
    <description>change in IKDC and KOOS score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stability of the clinical improvement documented with International Knee Documentation Committee (IKDC) score</measure>
    <time_frame>Time Frame: 6, 24 months evaluation</time_frame>
    <description>Change in IKDC Subjective score from baseline to follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stability of the clinical improvement documented with Knee Injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>Time Frame: 3,6, 12, 24 months evaluation</time_frame>
    <description>Change in KOOS score from baseline to follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of aMAT obtained with Lipogems® technology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>platelet-rich plasma (PRP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single injection of platelet-rich plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>injection of autologous micro-fragmented adipose tissue (aMAT)</intervention_name>
    <description>adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.</description>
    <arm_group_label>AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>injection of Platelet-rich Plasma (PRP)</intervention_name>
    <description>injection of platelet-rich plasma</description>
    <arm_group_label>platelet-rich plasma (PRP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patients provided written informed consent;

          2. Patients aged between 18 and 75 years;

          3. Knee symptomatic OA (Kellgren-Lawrence grade 1-4)

          4. Failure of conservative treatment for at least 3 months;

          5. Patients agreed to actively participate in the rehabilitation protocol and follow-up
             program;

          6. Male or female patients;

          7. Women of childbearing age had to use a proven method to prevent pregnancy, before the
             surgical treatment.

        Exclusion Criteria

          1. Patients incapable to understanding and will;

          2. Patients participating in previous, concurrent or not, trials (ongoing or completed
             within three months);

          3. Patients surgically treated for the same defect within one year;

          4. Patients affected by malignancy;

          5. Patients affected by metabolic or thyroid disorders;

          6. Patients used to alcohol or drug (medication) abuse;

          7. Patients affected by synovitis;

          8. Varus or valgus misalignment exceeding 15°;

          9. Body Mass Index &gt; 40;

         10. Patients with trauma within 6 months pre-operative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Versari</last_name>
    <role>Study Director</role>
    <affiliation>Lipogems International spa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Versari</last_name>
    <phone>+39 02 37072408</phone>
    <email>silvia.versari@lipogems.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marco Tiana</last_name>
    <phone>+39 02 37072408</phone>
    <email>marco.tiana@lipogems.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rizzoli Orthopaedic Institute</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurilio Marcacci</last_name>
      <email>m.marcacci@biomec.ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Filardo</last_name>
      <email>ortho@gfilardo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lipogems International spa</investigator_affiliation>
    <investigator_full_name>Prof. Marcacci</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>OA</keyword>
  <keyword>aMAT</keyword>
  <keyword>PRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

